Business
Voyageur Pharmaceuticals Ltd. Provides an Update and Prepares to Launch Initial Sales in Canada
(TheNewswire) Calgary, Alberta – TheNewswire - February 14, 2023 - Voyag...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Provides an Update and Prepares to Launch Initial Sales in Canada\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta –\n \n \n TheNewswire -\n \n \n February 14, 2023 -\n \n \n Voyageur Pharmaceuticals Ltd.\n \n \n (TSXV:VM)\n \n \n (\n \n \n OTC\n \n \n :VYYRF) (the \"Company\" or\n\"Voyageur\") continues to advance its sales and marketing\nprograms and is preparing to launch its first product, SmoothX™\nbarium sulfate CT contrast media oral suspension for the CT imaging\nmarket, in Canada.\n \n \n \n \n Voyageur announced today that Ethan Mohan has joined\nthe Company’s sales team as Canadian Sales Manager. Ethan will be\nresponsible for executing the Company’s sales program and has\nalready begun meeting with Government Health Service agencies and\nprivate clinics across Canada.\n \n \n \n \n \"From the start of the development of our barium\ncontrast media products, Voyageur has been committed to supporting the\nimaging market with high quality products that address the needs of\npatients and physicians alike. To this end, we are working closely\nwith our Scientific Advisory Board to develop scientific and practical\nbase materials that will support our customer-oriented sales\nprograms,\" said Brent Willis, President and CEO of Voyageur.\n \n \n \n \n The Company continues to advance the application for\nthe United States Federal Drug Agency (\"FDA\") approvals to\nmarket barium contrast products in the USA. In accordance with a\nFebruary 8, 2023 letter that Voyageur received from the FDA, barium\nsulfate products will continue to be regulated as drugs in the US\nmarket. As previously stated, Voyageur, in anticipation of this recent\ndecision by the FDA, has established all its product protocols,\nprocedures, and testing standards in accordance with FDA regulations\nand guidelines that apply to drugs.\n \n \n \n \n Based on these actions Voyageur continues to advance\nthe development and testing of four additional imaging products and is\nmoving forward positively as it relates to its first product\napplication for approval from the FDA in a timely manner.\n \n \n \n \n Voyageur announces that on\n \n \n \n January 16\n \n \n \n , 2023,\n \n \n it issued 383,790 Deferred\n \n \n Share Units\n(\"DSUs\") to d...